1. Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy.
- Author
-
Alnasraui, Ali Hussein F and Al-Musawi, Sharafaldin
- Subjects
- *
SQUAMOUS cell carcinoma , *GENETICS , *ZETA potential , *RESVERATROL , *APOPTOSIS , *POISONS , *NANOMEDICINE - Abstract
Among the vigorous anticancer agents, Resveratrol (RESV) has been demonstrated as a remarkable drug for treating most cancer types. The skin cancer cells (epidermoid carcinoma) indicate a high level of resistance to classical chemotherapy. previous researches exhibited that human serum albumin (HSA) nanostructure might have notable potential as nanocarrier in several medical aspects such as cancer therapy. The goal of the study is to demonstrate the ability of RESV drug delivery to HSA nanoparticles in skin cancer cells. Using the zeta sizer, the AFM, and FESEM and Using fluorescence microscopy following the loading of the RESV medicine with HSA, the Nano-device internalization profile has been determined. The suitable dose of prepared Nano formulation was then calculated with the MTT test for both cancerous and non-cancerous cell lines. Then the apoptosis induction assay was performed using flow cytometry. The characterization studies showed that fabricated nanostructure has a spherical shape with 200±17 nm in average hydrodynamic diameter, 0.012±1.4 polydispersity, and -41±0. Mv in zeta potential value. Meanwhile, the suitable RESV loading efficiency (-71%) was acquired. Both cytotoxic and programmed cell death studies confirmed noticeable toxic effects and apoptosis stimulation ratio. The RESV nanoformulation also indicated a controlled release of RESV at 37 °C in citrate and phosphate with acidic and normal pH respectively. All findings proved that the RESV nanoformulation has a significant toxic/apoptotic effect against cancerous cells and conversely was noticed that has not any toxic/apoptotic in normal cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF